Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial.

ABSTRACT:

Background

The purpose of this study was to evaluate the efficacy of buspirone, a partial 5-HT1A agonist, for treatment of cannabis dependence.

Methods

One hundred seventy-five cannabis-dependent adults were randomized to receive either up to 60mg/day of buspirone (n=88) or placebo (n=87) for 12 weeks combined with a brief motivational enhancement therapy intervention and contingency management to encourage study retention. Cannabis use outcomes were assessed via weekly urine cannabinoid tests.

Results

Participants in both groups reported reduced cannabis craving over the course of the study; however, buspirone provided no advantage over placebo in reducing cannabis use. Significant gender by treatment interactions were observed, with women randomized to buspirone hav

SUBMITTER: McRae-Clark AL 

PROVIDER: S-EPMC4633378 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature